Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

The Deubiquitinase Inhibitor b-AP15 and Its Effect on Phenotype and Function of Monocyte-Derived Dendritic Cells.

Schmidt M, Altdörfer V, Schnitte S, Fuchs AR, Kropp KN, Maurer S, Müller MR, Salih HR, Rittig SM, Grünebach F, Dörfel D.

Neoplasia. 2019 Jul;21(7):653-664. doi: 10.1016/j.neo.2019.03.001. Epub 2019 May 25.

2.

The novel deubiquitinase inhibitor b-AP15 induces direct and NK cell-mediated antitumor effects in human mantle cell lymphoma.

Kropp KN, Maurer S, Rothfelder K, Schmied BJ, Clar KL, Schmidt M, Strunz B, Kopp HG, Steinle A, Grünebach F, Rittig SM, Salih HR, Dörfel D.

Cancer Immunol Immunother. 2018 Jun;67(6):935-947. doi: 10.1007/s00262-018-2151-y. Epub 2018 Mar 19.

PMID:
29556699
3.

The BCR-ABL inhibitor nilotinib influences phenotype and function of monocyte-derived human dendritic cells.

Dörfel D, Lechner CJ, Joas S, Funk T, Gutknecht M, Salih J, Geiger J, Kropp KN, Maurer S, Müller MR, Kopp HG, Salih HR, Grünebach F, Rittig SM.

Cancer Immunol Immunother. 2018 May;67(5):775-783. doi: 10.1007/s00262-018-2129-9. Epub 2018 Feb 21.

PMID:
29468363
4.

Confirmation and next-generation sequencing of allele HLA-B*35:279 found in a family of a leukaemia patient with Western Asia origin.

Grünebach F, Huster AL, Vogel W, Klein R.

Int J Immunogenet. 2017 Feb;44(1):32-34. doi: 10.1111/iji.12299. Epub 2016 Dec 16.

PMID:
27987261
5.

Erratum to: The transcription factor MITF is a critical regulator of GPNMB expression in dendritic cells.

Gutknecht M, Geiger J, Joas S, Dörfel D, Salih HR, Müller MR, Grünebach F, Rittig SM.

Cell Commun Signal. 2016 May 17;14(1):11. No abstract available.

6.

Profiling of primary peripheral blood- and monocyte-derived dendritic cells using monoclonal antibodies from the HLDA10 Workshop in Wollongong, Australia.

Autenrieth SE, Grimm S, Rittig SM, Grünebach F, Gouttefangeas C, Bühring HJ.

Clin Transl Immunology. 2015 Nov 13;4(11):e50. doi: 10.1038/cti.2015.29. eCollection 2015 Nov.

7.

The transcription factor MITF is a critical regulator of GPNMB expression in dendritic cells.

Gutknecht M, Geiger J, Joas S, Dörfel D, Salih HR, Müller MR, Grünebach F, Rittig SM.

Cell Commun Signal. 2015 Mar 24;13:19. doi: 10.1186/s12964-015-0099-5. Erratum in: Cell Commun Signal. 2016;14(1):11.

8.

Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses.

Hilpert J, Grosse-Hovest L, Grünebach F, Buechele C, Nuebling T, Raum T, Steinle A, Salih HR.

J Immunol. 2012 Aug 1;189(3):1360-71. doi: 10.4049/jimmunol.1200796. Epub 2012 Jun 22.

9.

The immune inhibitory receptor osteoactivin is upregulated in monocyte-derived dendritic cells by BCR-ABL tyrosine kinase inhibitors.

Schwarzbich MA, Gutknecht M, Salih J, Salih HR, Brossart P, Rittig SM, Grünebach F.

Cancer Immunol Immunother. 2012 Feb;61(2):193-202. doi: 10.1007/s00262-011-1096-1. Epub 2011 Aug 27.

PMID:
21874302
10.

The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity.

Salih J, Hilpert J, Placke T, Grünebach F, Steinle A, Salih HR, Krusch M.

Int J Cancer. 2010 Nov 1;127(9):2119-28. doi: 10.1002/ijc.25233.

11.

CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells.

Baessler T, Charton JE, Schmiedel BJ, Grünebach F, Krusch M, Wacker A, Rammensee HG, Salih HR.

Blood. 2010 Apr 15;115(15):3058-69. doi: 10.1182/blood-2009-06-227934. Epub 2009 Dec 14. Erratum in: Blood. 2010 Dec 23;116(26):6152.

PMID:
20008791
12.

Immunomodulation by semi-mature dendritic cells: a novel role of Toll-like receptors and interleukin-6.

Frick JS, Grünebach F, Autenrieth IB.

Int J Med Microbiol. 2010 Jan;300(1):19-24. doi: 10.1016/j.ijmm.2009.08.010. Epub 2009 Sep 24. Review.

PMID:
19781988
13.

Characterization of BAX inhibitor-1 as a novel leukemia-associated antigen.

Schmidt SM, König T, Bringmann A, Held S, von Schwarzenberg K, Heine A, Holderried TA, Stevanovic S, Grünebach F, Brossart P.

Leukemia. 2009 Oct;23(10):1818-24. doi: 10.1038/leu.2009.138. Epub 2009 Jul 16.

PMID:
19609282
14.

Aberrant expression of the homeobox gene CDX2 in pediatric acute lymphoblastic leukemia.

Riedt T, Ebinger M, Salih HR, Tomiuk J, Handgretinger R, Kanz L, Grünebach F, Lengerke C.

Blood. 2009 Apr 23;113(17):4049-51. doi: 10.1182/blood-2008-12-196634. Epub 2009 Feb 13.

PMID:
19218548
15.

Post-transcriptional regulation of adapter molecules by IL-10 inhibits TLR-mediated activation of antigen-presenting cells.

Knödler A, Schmidt SM, Bringmann A, Weck MM, Brauer KM, Holderried TA, Heine AK, Grünebach F, Brossart P.

Leukemia. 2009 Mar;23(3):535-44. doi: 10.1038/leu.2008.301. Epub 2008 Nov 13.

PMID:
19005481
16.

Matrilysin (MMP-7) is a novel broadly expressed tumor antigen recognized by antigen-specific T cells.

Yokoyama Y, Grünebach F, Schmidt SM, Heine A, Häntschel M, Stevanovic S, Rammensee HG, Brossart P.

Clin Cancer Res. 2008 Sep 1;14(17):5503-11. doi: 10.1158/1078-0432.CCR-07-4041.

17.

Generation of antigen-specific CTL responses using RGS1 mRNA transfected dendritic cells.

Grünebach F, Erndt S, Häntschel M, Heine A, Brossart P.

Cancer Immunol Immunother. 2008 Oct;57(10):1483-91. doi: 10.1007/s00262-008-0486-5. Epub 2008 Feb 27.

PMID:
18301890
18.

The use of dendritic cells in cancer immunotherapy.

Nencioni A, Grünebach F, Schmidt SM, Müller MR, Boy D, Patrone F, Ballestrero A, Brossart P.

Crit Rev Oncol Hematol. 2008 Mar;65(3):191-9. Epub 2007 Dec 4. Review.

PMID:
18055210
19.

Identification of a lysosomal peptide transport system induced during dendritic cell development.

Demirel O, Waibler Z, Kalinke U, Grünebach F, Appel S, Brossart P, Hasilik A, Tampé R, Abele R.

J Biol Chem. 2007 Dec 28;282(52):37836-43. Epub 2007 Oct 31.

20.

hDectin-1 is involved in uptake and cross-presentation of cellular antigens.

Weck MM, Appel S, Werth D, Sinzger C, Bringmann A, Grünebach F, Brossart P.

Blood. 2008 Apr 15;111(8):4264-72. Epub 2007 Aug 13.

PMID:
17698636
21.

Histone deacetylase inhibitors affect dendritic cell differentiation and immunogenicity.

Nencioni A, Beck J, Werth D, Grünebach F, Patrone F, Ballestrero A, Brossart P.

Clin Cancer Res. 2007 Jul 1;13(13):3933-41.

22.

BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells.

Brauer KM, Werth D, von Schwarzenberg K, Bringmann A, Kanz L, Grünebach F, Brossart P.

Cancer Res. 2007 Jun 1;67(11):5489-97.

23.

Identification and characterization of T-cell epitopes deduced from RGS5, a novel broadly expressed tumor antigen.

Boss CN, Grünebach F, Brauer K, Häntschel M, Mirakaj V, Weinschenk T, Stevanovic S, Rammensee HG, Brossart P.

Clin Cancer Res. 2007 Jun 1;13(11):3347-55.

24.

The proteasome and its inhibitors in immune regulation and immune disorders.

Nencioni A, Grunebach F, Patrone F, Ballestrero A, Brossart P.

Crit Rev Immunol. 2006;26(6):487-98. Review.

PMID:
17341190
25.

Zoledronic acid inhibits the function of Toll-like receptor 4 ligand activated monocyte-derived dendritic cells.

Bringmann A, Schmidt SM, Weck MM, Brauer KM, von Schwarzenberg K, Werth D, Grünebach F, Brossart P.

Leukemia. 2007 Apr;21(4):732-8. Epub 2007 Feb 15.

PMID:
17301819
26.

TLR ligands differentially affect uptake and presentation of cellular antigens.

Weck MM, Grünebach F, Werth D, Sinzger C, Bringmann A, Brossart P.

Blood. 2007 May 1;109(9):3890-4. Epub 2007 Jan 11.

PMID:
17218388
27.

Proteasome inhibitors: antitumor effects and beyond.

Nencioni A, Grünebach F, Patrone F, Ballestrero A, Brossart P.

Leukemia. 2007 Jan;21(1):30-6. Epub 2006 Nov 9. Review.

PMID:
17096016
28.

Detection of a new JAK2 D620E mutation in addition to V617F in a patient with polycythemia vera.

Grünebach F, Bross-Bach U, Kanz L, Brossart P.

Leukemia. 2006 Dec;20(12):2210-1. Epub 2006 Sep 28. No abstract available.

PMID:
17008888
29.

BCR-ABL is not an immunodominant antigen in chronic myelogenous leukemia.

Grünebach F, Mirakaj V, Mirakaj V, Müller MR, Brümmendorf T, Brossart P.

Cancer Res. 2006 Jun 1;66(11):5892-900.

30.

Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation.

Nencioni A, Schwarzenberg K, Brauer KM, Schmidt SM, Ballestrero A, Grünebach F, Brossart P.

Blood. 2006 Jul 15;108(2):551-8. Epub 2006 Mar 14.

PMID:
16537813
31.

Epithelial-specific transcription factor ESE-3 is involved in the development of monocyte-derived DCs.

Appel S, Bringmann A, Grünebach F, Weck MM, Bauer J, Brossart P.

Blood. 2006 Apr 15;107(8):3265-70. Epub 2005 Dec 27.

PMID:
16380452
32.

Transfection of dendritic cells with in vitro-transcribed CMV RNA induces polyclonal CD8+- and CD4+-mediated CMV-specific T cell responses.

Heine A, Grünebach F, Holderried T, Appel S, Weck MM, Dörfel D, Sinzger C, Brossart P.

Mol Ther. 2006 Feb;13(2):280-8. Epub 2005 Oct 10.

33.

PPAR-gamma agonists inhibit toll-like receptor-mediated activation of dendritic cells via the MAP kinase and NF-kappaB pathways.

Appel S, Mirakaj V, Bringmann A, Weck MM, Grünebach F, Brossart P.

Blood. 2005 Dec 1;106(12):3888-94. Epub 2005 Aug 16.

PMID:
16105976
34.

Cotransfection of dendritic cells with RNA coding for HER-2/neu and 4-1BBL increases the induction of tumor antigen specific cytotoxic T lymphocytes.

Grünebach F, Kayser K, Weck MM, Müller MR, Appel S, Brossart P.

Cancer Gene Ther. 2005 Sep;12(9):749-56.

PMID:
15877082
35.

New developments in dendritic cell-based vaccinations: RNA translated into clinics.

Grünebach F, Müller MR, Brossart P.

Cancer Immunol Immunother. 2005 Jun;54(6):517-25. Epub 2005 Jan 27. Review.

PMID:
15838706
36.

Effects of imatinib on monocyte-derived dendritic cells are mediated by inhibition of nuclear factor-kappaB and Akt signaling pathways.

Appel S, Rupf A, Weck MM, Schoor O, Brümmendorf TH, Weinschenk T, Grünebach F, Brossart P.

Clin Cancer Res. 2005 Mar 1;11(5):1928-40.

37.

Processing and presentation of HLA class I and II epitopes by dendritic cells after transfection with in vitro-transcribed MUC1 RNA.

Dörfel D, Appel S, Grünebach F, Weck MM, Müller MR, Heine A, Brossart P.

Blood. 2005 Apr 15;105(8):3199-205. Epub 2004 Dec 23.

PMID:
15618468
38.

RNA transfection of dendritic cells.

Grünebach F, Müller MR, Brossart P.

Methods Mol Med. 2005;109:47-54.

PMID:
15585912
39.

Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study.

Brugger W, Hirsch J, Grünebach F, Repp R, Brossart P, Vogel W, Kopp HG, Manz MG, Bitzer M, Schlimok G, Kaufmann M, Ganser A, Fehnle K, Gramatzki M, Kanz L.

Ann Oncol. 2004 Nov;15(11):1691-8.

PMID:
15520073
40.

Identification of C-met oncogene as a broadly expressed tumor-associated antigen recognized by cytotoxic T-lymphocytes.

Schag K, Schmidt SM, Müller MR, Weinschenk T, Appel S, Weck MM, Grünebach F, Stevanovic S, Rammensee HG, Brossart P.

Clin Cancer Res. 2004 Jun 1;10(11):3658-66.

41.

CDCP1 identifies a broad spectrum of normal and malignant stem/progenitor cell subsets of hematopoietic and nonhematopoietic origin.

Bühring HJ, Kuçi S, Conze T, Rathke G, Bartolović K, Grünebach F, Scherl-Mostageer M, Brümmendorf TH, Schweifer N, Lammers R.

Stem Cells. 2004;22(3):334-43.

42.

Induction of adipophilin-specific cytotoxic T lymphocytes using a novel HLA-A2-binding peptide that mediates tumor cell lysis.

Schmidt SM, Schag K, Müller MR, Weinschenk T, Appel S, Schoor O, Weck MM, Grünebach F, Kanz L, Stevanovic S, Rammensee HG, Brossart P.

Cancer Res. 2004 Feb 1;64(3):1164-70.

43.

Induction of chronic lymphocytic leukemia (CLL)-specific CD4- and CD8-mediated T-cell responses using RNA-transfected dendritic cells.

Müller MR, Tsakou G, Grünebach F, Schmidt SM, Brossart P.

Blood. 2004 Mar 1;103(5):1763-9. Epub 2003 Nov 13.

PMID:
14615377
44.

Cyclopentenone prostaglandins induce lymphocyte apoptosis by activating the mitochondrial apoptosis pathway independent of external death receptor signaling.

Nencioni A, Lauber K, Grünebach F, Van Parijs L, Denzlinger C, Wesselborg S, Brossart P.

J Immunol. 2003 Nov 15;171(10):5148-56.

45.

Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells.

Appel S, Boehmler AM, Grünebach F, Müller MR, Rupf A, Weck MM, Hartmann U, Reichardt VL, Kanz L, Brümmendorf TH, Brossart P.

Blood. 2004 Jan 15;103(2):538-44. Epub 2003 Sep 22.

PMID:
14504105
46.

Expression of her-2/neu on acute lymphoblastic leukemias: implications for the development of immunotherapeutic approaches.

Müller MR, Grünebach F, Kayser K, Vogel W, Nencioni A, Brugger W, Kanz L, Brossart P.

Clin Cancer Res. 2003 Aug 15;9(9):3448-53.

48.

Dendritic cells transfected with tumor RNA for the induction of antitumor CTL in colorectal cancer.

Nencioni A, Müller MR, Grünebach F, Garuti A, Mingari MC, Patrone F, Ballestrero A, Brossart P.

Cancer Gene Ther. 2003 Mar;10(3):209-14.

PMID:
12637942
49.

Heterogeneity among human bone marrow-derived mesenchymal stem cells and neural progenitor cells.

Vogel W, Grünebach F, Messam CA, Kanz L, Brugger W, Bühring HJ.

Haematologica. 2003 Feb;88(2):126-33.

50.

Delivery of tumor-derived RNA for the induction of cytotoxic T-lymphocytes.

Grünebach F, Müller MR, Nencioni A, Brossart P.

Gene Ther. 2003 Mar;10(5):367-74.

PMID:
12601391

Supplemental Content

Loading ...
Support Center